替吉奥联合顺铂新辅助化疗治疗食管癌的临床效果分析

Clinical effect analysis of tegafur gimeracil oteracil combined with cisplatin neoadjuvant chemotherapy in treatment of esophageal cancer

目的 探讨替吉奥联合顺铂新辅助化疗对食管癌患者的临床治疗效果。方法 回顾性分析我院2011年1月~2012年12月间收治的70例食管癌患者,采用随机数字表法分为对照组和研究组,每组各35例。对照组患者不进行辅助化疗,直接行根治性切除手术,研究组患者则在术前采用替吉奥联合顺铂新辅助化疗,比较两组病例的根治性手术切除率、术后并发症情况以及3年存活率。结果 对照组35例患者中,24例切除成功,切除率为68.6%;研究组35例患者中,31例切除成功,切除率为88.6%。研究组患者手术切除率要高于对照组,差异具有统计学意义（χ2=8.036,P〈0.05）;对照组患者术后并发症发生率为28.6%,研究组患者术后并发症发生率为17.1%,研究组患者的术后并发症发生率低于对照组,差异有统计学意义（χ2=6.371,P〈0.05）;经过随访,对照组患者3年存活率为31.4%,研究组患者3年存活率为57.1%,研究组患者3年存活率高于对照组,差异具有统计学意义（χ2=6.881,P〈0.05）。结论 食管癌患者采用替吉奥联合顺铂新辅助化疗治疗,不仅手术切除率高,术后并发症发生率低,还能显著提高患者3年存活率,可在临床推广应用。

Objective To discuss the clinical effect of tegafur gimeracil oteracil combined with cisplatin neoadjuvant chemotherapy in treatment of esophageal cancer. Methods A total of 70 patients with esophageal cancer treated in our hospital from January 2011 to December 2012 were retrospectively analyzed and divided into control group and study group by the random number table, with 35 cases in each group. Patients in control group were directly treated by radical excision without adjuvant chemotherapy, while patients in study group were given tegafur gimeracil oteracil com- bined with cispiatin neoadjuvant chemotherapy before operation. The radical resection rate, complications after operation and three-year survival rate were compared between two groups. Results Of the 35 patients in the control group, 24 cases （68.6%） were successfully resected; and in the study group, 31 cases （88.6%） were successfully resected. The resection rate was significantly higher in the study group than in the control group 0（2=8.036, P〈0.05）. The incidence rate of complications was 28.6% in the control group which was significantly higher than the 17.1% in the study group （χ2=6.371, P〈0.05）. According to the result of following up, the 3-year survival rate was 31.4% in the control group, which was significantly lower than the 57.1% in the study group （χ2=6.881, P〈0.05）. Conclusion Application of tegafur gimeracil oteracil combined with cisplatin neoadjuvant chemotherapy in treatment of esophageal cancer can bring higher resection rate with lower incidence of complications, and can also significantly improve the 3-year survival rate of patients, thus is worthy to be promoted.